Connect Biopharma initiates Phase 2 Seabreeze STAT COPD study

Connect Biopharma (CNTB) Holdings announced the initiation of its Phase 2 Seabreeze STAT COPD study following written agreement on the final study protocol from the U.S. Food and Drug Administration. The study will evaluate the safety and efficacy of rademikibart as an adjunct to standard of care for acute exacerbations in participants with COPD and type 2 inflammation. “The initiation of our second Phase 2 study in patients with inflammatory lung disease highlights our commitment to swiftly advancing the development of rademikibart for asthma and COPD,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “In the current treatment landscape for patients experiencing an acute exacerbation with asthma or COPD, there are no approved biologics that can rapidly improve lung function and prevent further exacerbations over the short- and long-term. Based on our recently published Phase 2 data we believe rademikibart holds the potential to be the first biologic to deliver on this promise.”